Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care

AACR 2018: First-Line Management of Advanced NSCLC Enters New Era

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

PACIFIC Trial Leads to Durvalumab Approval in United States

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

ALK Testing in Europe

Immunotherapy Adverse-Event Treatment Resource Guide

Management of Immunotherapy Toxicity in NSCLC